US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -1.15 against a street estimate of -1.20 — a beat of 4.2%.
Analysts rate Sunshine Biopharma Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $1,120.00.
| Fund | Stake |
|---|---|
| Jane Street Group LLC | 0.35% |
| Morgan Stanley - Brokerage Accounts | 0.01% |
| SBI Securities Co Ltd | 0.00% |
| NATIONAL BANK OF CANADA /FI/ | 0.00% |
| Advisor Group Holdings, Inc. | 0.00% |
| TD Waterhouse Canada Inc | 0.00% |
| Caitong International Asset Management Co., Limited. | 0.00% |
| Strive Financial Group ,LLC | 0.00% |
| Action | Detail | Date |
|---|---|---|
| Split | 1 : 20 effective Oct 26, 2026 | 2026-10-26 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sunshine Biopharma Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.